Skip to main content

Vulvodynia

1
Pipeline Programs
6
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Initiator Pharma
Initiator PharmaDenmark - Copenhagen
1 program
1
PudafensinePhase 21 trial
Active Trials
NCT07391241Recruiting24Est. Dec 2026
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
Cognitive-Behavioral TherapyN/A1 trial
VulvodyniaN/A1 trial
Active Trials
NCT00607490Completed50Est. Mar 2005
NCT02404961Completed30,675Est. Dec 2014
Ipsen
IpsenChina - Tianjin
2 programs
Validation of Patient Reported Outcome Measures for Use in VulvodyniaN/A1 trial
Botulinum toxin type APHASE_21 trial
Active Trials
NCT03770169Completed20Est. Sep 2019
NCT03598777Terminated60Est. Jan 2021
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Profiling Vulvodynia Based on Neurobiological and Behavioral EndophenotypesN/A1 trial
Active Trials
NCT02733172Completed168Est. Jun 2018
Bristol Myers Squibb
1 program
CC-10004PHASE_21 trial
Active Trials
NCT00814632Completed10Est. Feb 2011
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
Topical liquid lidocainePHASE_31 trial
Active Trials
NCT01539317Completed50Est. Nov 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Knight TherapeuticsTopical liquid lidocaine
Initiator PharmaPudafensine
IpsenBotulinum toxin type A
Bristol Myers SquibbCC-10004
IpsenValidation of Patient Reported Outcome Measures for Use in Vulvodynia
Angeles TherapeuticsProfiling Vulvodynia Based on Neurobiological and Behavioral Endophenotypes
Human BioSciencesVulvodynia
Human BioSciencesCognitive-Behavioral Therapy

Clinical Trials (8)

Total enrollment: 31,057 patients across 8 trials

NCT01539317Knight TherapeuticsTopical liquid lidocaine

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

Start: Dec 2011Est. completion: Nov 201350 patients
Phase 3Completed
NCT07391241Initiator PharmaPudafensine

A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia)

Start: Dec 2025Est. completion: Dec 202624 patients
Phase 2Recruiting
NCT03598777IpsenBotulinum toxin type A

Dysport in Vulvodynia Phase II Study

Start: Jun 2018Est. completion: Jan 202160 patients
Phase 2Terminated
NCT00814632Bristol Myers SquibbCC-10004

CC-10004 For The Treatment Of Vulvodynia

Start: Dec 2008Est. completion: Feb 201110 patients
Phase 2Completed
NCT03770169IpsenValidation of Patient Reported Outcome Measures for Use in Vulvodynia

Validation of Patient Reported Outcome Measures for Use in Vulvodynia

Start: Feb 2019Est. completion: Sep 201920 patients
N/ACompleted
NCT02733172Angeles TherapeuticsProfiling Vulvodynia Based on Neurobiological and Behavioral Endophenotypes

Profiling Vulvodynia Based on Neurobiological and Behavioral Endophenotypes

Start: Jul 2013Est. completion: Jun 2018168 patients
N/ACompleted
NCT02404961Human BioSciencesVulvodynia

Women's Health Study: Immunological Factors and Risk of Vulvodynia

Start: Sep 2009Est. completion: Dec 201430,675 patients
N/ACompleted
NCT00607490Human BioSciencesCognitive-Behavioral Therapy

A Randomized Clinical Trial for Women With Vulvodynia

Start: Sep 2000Est. completion: Mar 200550 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 31,057 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.